Structure-Based Methods for the Prediction of the Dominant P450 Enzyme in Human Drug Biotransformation: Consideration of CYP3A4, CYP2C9, CYP2D6
暂无分享,去创建一个
[1] P. Anzenbacher,et al. Cytochromes P450 and metabolism of xenobiotics , 2001, Cellular and Molecular Life Sciences CMLS.
[2] S. Ekins,et al. Application of in silico approaches to predicting drug--drug interactions. , 2001, Journal of pharmacological and toxicological methods.
[3] Oleg A. Raevsky. Hydrogen Bond Strength Estimation by Means of the HYBOT Program Package , 2007 .
[4] B G Woodcock,et al. Systematic screening for pharmacokinetic interactions during drug development. , 1996, International journal of clinical pharmacology and therapeutics.
[5] Roger L. Black,et al. Goodman and Gilman's The Pharmacological Basis of Therapeutics , 1991 .
[6] G. Granneman,et al. Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions , 1997, Clinical pharmacokinetics.
[7] D. Lewis,et al. On the recognition of mammalian microsomal cytochrome P450 substrates and their characteristics: towards the prediction of human p450 substrate specificity and metabolism. , 2000, Biochemical pharmacology.
[8] Elizabeth Landrum Michalets,et al. Update: Clinically Significant Cytochrome P‐450 Drug Interactions , 1998, Pharmacotherapy.
[9] T. Shimada,et al. Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. , 1991, Chemical research in toxicology.
[10] D. Mansuy,et al. The substrate binding site of human liver cytochrome P450 2C9: an approach using designed tienilic acid derivatives and molecular modeling. , 1995, Biochemistry.
[11] D A Smith,et al. Putative active site template model for cytochrome P4502C9 (tolbutamide hydroxylase). , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[12] Maurice Dickins,et al. Substrate SARs in human P450s. , 2002, Drug discovery today.
[13] Steven L. Dixon,et al. Use of Robust Classification Techniques for the Prediction of Human Cytochrome P450 2D6 Inhibition , 2003, J. Chem. Inf. Comput. Sci..
[14] Danielson Pb,et al. The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. , 2002 .
[15] P. Danielson,et al. The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. , 2002, Current drug metabolism.
[16] A. Tropsha,et al. Development and validation of k-nearest-neighbor QSPR models of metabolic stability of drug candidates. , 2003, Journal of medicinal chemistry.
[17] Sean Ekins,et al. Pharmacophore modeling of cytochromes P450. , 2002, Advanced drug delivery reviews.
[18] Dennis A. Smith,et al. Properties of cytochrome P450 isoenzymes and their substrates Part 2: properties of cytochrome P450 substrates , 1997 .